Comparative assessment of the effects of dobutamine and levosimendan on right ventricular ejection fraction in patients with biventricular heart failure

Aim    The primary objective of this study was to comparatively assess the effects of levosimendan and dobutamine on RVEF, right ventricular diastolic function, and hormonal balance in patients with biventricular heart failure. The secondary objective was to investigate the relationship between the RVEF and the peak systolic velocity (Sa), an indicator of right ventricular systolic function, as measured by tissue Doppler echocardiography from the tricuspid annulus, and by the tricuspid annular plane systolic excursion (TAPSE).
Material and Methods    The population of this cross-sectional, single-center, prospective study was comprised of 81 patients, who between December 2019 and January 2022, applied to the study health institution with diagnosis of ADHF. The study sample included 67 biventricular heart failure patients with left ventricular ejection fraction (LVEF) <35 % and RVEF <50 %, as measured by the ellipsoidal shell model, and who met the other study inclusion criteria. Of these 67 patients, 34 were treated with levosimendan, and 33 were treated with dobutamine. RVEF, LVEF, Sa, peak early (Ea) and peak late (Aa) annular velocities, Ea / Aa ratio, TAPSE, systolic pulmonary artery pressure (SPAP), n-terminal pro-brain natriuretic peptide (NT-pro BNP), and functional capacity (FC) were measured before treatment and at 48 hrs of treatment. The within group pre- and post-treatment differences (Δs) of these variables were compared.
Results    RVEF, SPAP, and BNP, and FC significantly improved in both treatment groups (p<0.05 for all). Sa (p<0.01), TAPSE (p<0.01), LVEF (p<0.01), and Ea / Aa (p<0.05) improved only in the levosimendan group. The pre- and post-treatment Δs for RVEF, LVEF, SPAP, Sa, TAPSE, FC, and Ea / Aa were higher in the levosimendan group than in the dobutamine group (p<0.05 for all).
Conclusion    Compared to dobutamine, levosimendan produced greater improvement in right ventricular systolic and diastolic function in patients with biventricular heart failure and in need of inotropic therapy support.

1. Guerrero-Orriach JL, Ramirez Fernandez A., Iglesias P., Galan M., Melero Jm., Florez A. et al. Preoperative Levosimendan. A New Way for Organoprotection. Current Pharmaceutical Design. 2014;20(34):5476–83. DOI: 10.2174/1381612820666140325121452

2. Chang H-Yu, Wang Ch-Ch, Wu Ye-W, Chu P-H, Wu Ch-Ch, Hsu Ch H et al. One-Year Outcomes of Acute Decompensated Systolic Heart Failure in Taiwan: Lessons from TSOC-HFrEF Registry. Acta Cardiologica Sinica. 2017;33(2):127–38. DOI: 10.6515/ACS20170202A

3. Guerrero-Orriach JL, Ariza-Villanueva D, Florez-Vela A, GarridoSánchez L, Moreno-Cortés MI, Galán-Ortega M et al. Cardiac, renal, and neurological benefits of preoperative levosimendan administration in patients with right ventricular dysfunction and pulmonary hypertension undergoing cardiac surgery: evaluation with two biomarkers neutrophil gelatinase-associated lipocalin and neuronal enolase. Therapeutics and Clinical Risk Management. 2016;12:623–30. DOI: 10.2147/TCRM.S102772

4. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V et al. Survival in Patients With Idiopathic, Familial, and AnorexigenAssociated Pulmonary Arterial Hypertension in the Modern Management Era. Circulation. 2010;122(2):156–63. DOI: 10.1161/CIRCULATIONAHA.109.911818

5. D’Alonzo GE, Barst RJ, Ayres SM, Brundage BH, Detre KM, Fishman AP et al. Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry. Annals of Internal Medicine. 1991;115(5):343–9. DOI: 10.7326/0003-4819-115-5-343

6. Perrone SV, Kaplinsky EJ. Calcium sensitizer agents: A new class of inotropic agents in the treatment of decompensated heart failure. International Journal of Cardiology. 2005;103(3):248–55. DOI: 10.1016/j.ijcard.2004.12.012

7. Kasikcioglu HA, Uyarel H, Tartan Z, Kasikcioglu E, Ozturk R, Cam N. Do calcium sensitizers affect right ventricular functions in patients with chronic heart failure? International Journal of Cardiology. 2007;118(2):246–8. DOI: 10.1016/j.ijcard.2006.06.054

8. Parissis JT, Paraskevaidis I, Bistola V, Farmakis D, Panou F, Kourea K et al. Effects of levosimendan on right ventricular function in patients with advanced heart failure. The American Journal of Cardiology. 2006;98(11):1489–92. DOI: 10.1016/j.amjcard.2006.06.052

9. Kovalova S, Necas J, Cerbak R, Malik P, Vespalec J. Echocardiographic volumetry of the right ventricle. European Journal of Echocardiography. 2005;6(1):15–23. DOI: 10.1016/j.euje.2004.04.009

10. Denslow S. An Ellipsoidal Shell Model for Volume Estimation of the Right Ventricle from Magnetic Resonance Images. Academic Radiology. 1994;1(4):345–51. DOI: 10.1016/S1076-6332(12)80006-7

11. Jiang L, Handschumacher MD, Hibberd MG, Siu SC, King ME, Weyman AE et al. Three-dimensional Echocardiographic Reconstruction of Right Ventricular Volume: In Vitro Comparison With Two-Dimensional Methods. Journal of the American Society of Echocardiography. 1994;7(2):150–8. DOI: 10.1016/S0894-7317(14)80120-X

12. Vogel M, Gutberlet M, Dittrich S, Hosten N, Lange PE. Comparison of transthoracic three dimensional echocardiography with magnetic resonance imaging in the assessment of right ventricular volume and mass. Heart. 1997;78(2):127–30. DOI: 10.1136/hrt.78.2.127

13. Duygu H, Ozerkan F, Zoghi M, Nalbantgil S, Yildiz A, Akilli A et al. Effect of levosimendan on right ventricular systolic and diastolic functions in patients with ischaemic heart failure. International Journal of Clinical Practice. 2008;62(2):228–33. DOI: 10.1111/j.1742-1241.2007.01510.x

14. Parissis JT, Panou F, Farmakis D, Adamopoulos S, Filippatos G, Paraskevaidis I et al. Effects of Levosimendan on Markers of Left Ventricular Diastolic Function and Neurohormonal Activation in Patients With Advanced Heart Failure. The American Journal of Cardiology. 2005;96(3):423–6. DOI: 10.1016/j.amjcard.2005.03.092

15. Tachibana H, Cheng H-J, Ukai T, Igawa A, Zhang Z-S, Little WC et al. Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure. American Journal of Physiology-Heart and Circulatory Physiology. 2005;288(2):H914–22. DOI: 10.1152/ajpheart.00465.2004

16. Ukkonen H. Myocardial efficiency during levosimendan infusion in congestive heart failure. Clinical Pharmacology & Therapeutics. 2000;68(5):522–31. DOI: 10.1067/mcp.2000.110972

17. Leather HA, Ver Eycken K, Segers P, Herijgers P, Vandermeersch E, Wouters PF. Effects of levosimendan on right ventricular function and ventriculovascular coupling in open chest pigs. Critical Care Medicine. 2003;31(9):2339–43. DOI: 10.1097/01.CCM.0000084844.95073.C0

18. Kerbaul F, Rondelet B, Motte S, Fesler P, Hubloue I, Ewalenko P et al. Effects of norepinephrine and dobutamine on pressure load-induced right ventricular failure. Critical Care Medicine. 2004;32(4):1035–40. DOI: 10.1097/01.CCM.0000120052.77953.07

19. Wang Y-B, Hao G-Z, Jiang Y-F, Fu X-H, Fan W-Z, Miao Q et al. Effects of Levosimendan on Right Ventricular Function in Patients with Acute Decompensated Heart Failure. Acta Cardiologica Sinica. 2019;35(6):585–91. DOI: 10.6515/ACS.201911_35(6).20190327A

20. Dernellis J, Panaretou M. Effects of Levosimendan on Restrictive Left Ventricular Filling in Severe Heart Failure: a combined hemodynamic and Doppler echocardiographic study. Chest. 2005;128(4):2633–9. DOI: 10.1378/chest.128.4.2633